GMAB
Genmab ADR
7월 27일 2:38 PM ET (한국 7/28 03:38)
$28.87
-0.30 ▼ -1.03%
젠맙(GMAB) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
시가총액
$17.2B
미드캡
P/E
21.8
적정 수준
배당수익률
없음
52주 위치
55%
저점 +38% · 고점 -19%
애널리스트
적극 매수
B-
Fundamental health
vs. 성장주 대형주
수익성 Top 33%
성장 Top 42%
밸류에이션 Top 66%
재무 안정 Top 40%
| Index | - | P/E | 21.77 | EPS (ttm) | 1.33 | Insider Own | 0.52% | Shs Outstand | 613.8M | Perf Week | 0.52% |
| Market Cap | 17.18B | Forward P/E | 17.14 | EPS next Y | 48.81% | Insider Trans | - | Shs Float | 591.9M | Perf Month | 11.62% |
| Enterprise Value | 21.01B | PEG | 0.98 | EPS next Q | 0.35 | Inst Own | 13.49% | Short Float | 1.41% | Perf Quarter | 7.01% |
| Income | 0.82B | P/S | 4.39 | EPS this Y | -26.34% | Inst Trans | -0.21% | Short Ratio | 4.29 | Perf Half Y | -12.78% |
| Sales | 3.91B | P/B | 3.12 | EPS next 5Y | 17.57% | ROA | 8.69% | Short Interest | 8.33M | Perf YTD | -6.27% |
| Book/sh | 9.26 | P/C | 11.29 | EPS past 3/5Y | 9.68% 6.84% | ROE | 15.01% | 52W High | -18.52% ($35.43) | Perf Year | 22.18% |
| Cash/sh | 2.56 | P/FCF | 19.62 | Sales past 3/5Y | 22.11% 19.27% | ROIC | 7.67% | 52W Low | 37.51% ($21.00) | Perf 3Y | -27.43% |
| Dividend Est. | - | EV/EBITDA | 15.28 | EPS Y/Y TTM | -24.83% | Gross Margin | 93.31% | Volatility(W/M) | 2.37% 2.48% | Perf 5Y | -35.63% |
| Dividend TTM | - | EV/Sales | 5.37 | Sales Y/Y TTM | 21.02% | Oper. Margin | 32.99% | ATR (14) | 0.81 | Perf 10Y | 70.28% |
| Dividend Ex-Date | - | Quick Ratio | 2.17 | EPS Q/Q | -72.71% | Profit Margin | 21.06% | RSI (14) | 58.31 | Recom | 1.32 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.18 | Sales Q/Q | 25.69% | SMA20 | 1.52% ($28.44) | Beta | 0.82 | Target Price | $37.68 |
| Payout | - | Debt/Eq | 0.94 | Earnings | 2026/5/7 | SMA50 | 7.71% ($26.8) | Rel Volume | 0.86 | Prev Close | $29.17 |
| Employees | 3029 | LT Debt/Eq | 0.89 | EPS/Sales Surpr. | -46.69% -1.08% | SMA200 | -0.94% ($29.14) | Avg Volume(3M) | 1.94M | Price | $28.87 |
| IPO | 2009/6/1 | Option/Short | Yes/Yes | Trades | 14032 | Volume | 1,676,218 | Change | -1.03% |
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.
Genmab ADR (GMAB) Investment Analysis
What kind of company is Genmab ADR?
젠맙(GMAB) 성장주
Healthcare · Biotechnology
#668 by Market Cap — Mid-Cap
A Denmark-based biotech company specializing in antibody therapeutics. Leveraging its proprietary antibody technology platform, it develops anticancer antibody drugs and generates revenue through collaborations with multinational pharmaceutical companies as well as its own in-house drug products, positioning it as a global antibody therapeutics company.
Learn more about Genmab ADR →Market Cap
$17.2B
Approx. KRW 23.5 trillion
⚖️ 6% of Samsung Electronics
Market Cap Rank668
Employees3,029people
IPO2009/06/01
Current Price$28.87 ≈ 39,552원
Key Events
⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 7일 (목) · 장 마감 후 EPS -46.7% 매출 -1.1%
🔔 Earnings release 2026년 2월 17일 (화) · 장 마감 후 EPS -74.3% 매출 -0.8%
Is it profitable?
Solid company — profitability & finances both healthy
Strong earnings and excellent financial health
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
33.0%
✓ 우수
Net Margin
Share of revenue left after taxes and interest are paid
21.1%
✓ 양호
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
93.3%
✓ 우수
ROE
Annual return earned on shareholders' equity (15%+ is strong)
15.0%
✓ 양호
ROA
Annual earnings relative to total company assets
8.7%
✓ 양호
ROIC
Return generated per dollar invested in the business
7.7%
✓ 양호
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.94
✓ Average
Current Ratio
Liquid assets available to cover liabilities due within a year
2.18
✓ 양호
Quick Ratio
Liquid assets excluding inventory, available for immediate use
2.17
✓ 양호
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).
What's the outlook?
Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$37.68
현재가 대비 +30.5%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
17.14배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
PEG (성장 반영 밸류)
0.98
저평가
💡 PEG < 1 — 성장 대비 저렴
내년 EPS 예상 성장률
+48.8%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+17.6%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.
Did earnings meet expectations?
High Earnings Volatility
Frequently misses analyst estimates
0
예상 상회
0
예상 부합
2
예상 하회
0%
상회 비율
-37.1%
평균 서프라이즈
2026.05.07
하회
실적 $0.13 · 예상 $0.19 -29.7%
2026.02.17
하회
실적 $0.21 · 예상 $0.37 -44.5%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.
Is it growing?
Average Growth
Mid-range within the industry
Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
-26.3%
매우 부진
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+48.8%
우수
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+17.6%
양호
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+9.7%
양호
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+6.8%
부진
Past 5-Year Revenue
How much revenue grew over the past 5 years
+19.3%
우수
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+25.7%
우수
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →
Has the stock risen over the long term?
Long-term weakness — -104%p below the market
GMAB -35.6% · S&P 500 +68.0%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-103.6%p
Significantly behind the market
vs Health Care (XLV)
-59.3%p
Significantly behind the sector average
1-year basis
vs S&P 500
+5.7%p
slightly ahead of the market
vs Health Care (XLV)
+2.4%p
roughly in line with the sector average
Rank among peers
5-year return Bottom 11% Based on 24 peers
1-year return Lower-Mid (lower 35%) Based on 24 peers
Current position within 52-week range
Low (-37.5%p) High (-18.5%p)
Current price is 37.5% above the 52-week low and 18.5% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-27.8%
Annualized volatility
33.3%
Technical Indicators
Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series
Price · Bollinger Bands · Ichimoku Cloud
- close
- BB Upper
- BB Mid
- BB Lower
- Tenkan
- Kijun
- Cloud (SpanA/B)
Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →
Current diagnosis · 2026-07-24
Uptrend zone
Current price $28.87 above the midline ($28.44). Normal upward flow. Above the Ichimoku cloud (bullish).
MACD (12 · 26 · 9) Expand ▼
An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →
Current diagnosis · 2026-07-24
Neutral zone — weak trend
MACD 0.632 · Signal 0.693 · Hist -0.061. Weak directional bias.
RSI(14) · Stochastics %K(14) Expand ▼
RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →
Current diagnosis · 2026-07-24
Bullish zone
RSI 58.3 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 52.1.
※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.
Is it attractive at this price?
Cheaper than peers in its industry
Cheap on Vs. Earnings·Vs. Assets·Vs. Sales·Vs. Cash Flow
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
Vs. Earnings Cheap
Vs. Assets Cheap
Vs. Sales Cheap
Vs. Cash Flow Cheap
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
21.77x
✓ Fair
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
17.14x
✓ Cheap
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
3.12x
✓ Very cheap
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
4.39x
✓ Very cheap
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
15.28x
✓ Cheap
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
19.62x
✓ Fair
Analyst target price (reference)
$37.68 vs. current price +30.5%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology
Who owns it?
Ownership is broadly stable
Institutional modest net selling -0.2% · Short interest light 1.4%
📈 Recent trading flow (6 months)
🧑💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
-0.2%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 13.5%
Retail-led
🧑💼 Insiders 0.5%
Low, common among large-caps
👤 Retail investors (estimated) 86.0%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
1.4%
Low — limited short-side pressure
Past 90 days Little change
Short interest days to cover
4.3 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 613.8M주
Float (tradable shares) 591.9M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.
ETFs holding GMAB
ETFs with the highest weightings · 10 total shown
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.
How much does it pay in dividends?
This company does not pay a dividend
It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.
Compare Industry Peers
💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
| Stock | Market Cap | PER | PBR | ROE | Dividend Yield | Change |
|---|---|---|---|---|---|---|
| GMAB This Stock | $17.2B | 21.8 ▲ | 3.1 ▼ | 15.01% ▲ | - | -1.0% |
LLY | $1.13T | 43.0 ▼ | 36.2 ▼ | 107.64% ▲ | 0.58% ▼ | +0.9% |
JNJ | $634.1B | 30.5 ▼ | 7.5 ▼ | 25.74% ▲ | 2.04% ▲ | +1.6% |
ABBV | $458.2B | 127.9 ▼ | - | 15221.82% ▲ | 2.65% ▲ | +0.9% |
UNH | $382.1B | 27.1 ▼ | 3.9 ▼ | 12.49% ▲ | 2.15% ▲ | -0.7% |
MRK | $323.7B | 36.9 ▼ | 7.1 ▼ | 18.97% ▲ | 2.49% ▲ | +0.5% |
| Sector Avg | - | 25.8 | 2.7 | -48.83% | 1.25% | - |
FAQ
What kind of company is 젠맙(GMAB)?
젠맙(GMAB) belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GMAB?
The market cap of GMAB is approximately $17.2B, ranking 668 within its sector.
What is the P/E ratio of GMAB?
GMAB has a P/E ratio of approximately 21.8x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for GMAB?
GMAB has recorded a 52-week high of $35.43 and a low of $21.00.
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.